Jane Street
ABCL icon

Jane Street’s AbCellera Biologics ABCL Stock Holding History

Jane Street’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$578K Buy
165,700
+66,300
+67% +$239K ﹤0.01% 7705
2025
Q4 		$340K Buy
99,400
+40,700
+69% +$182K ﹤0.01% 8544
2025
Q3 		$295K Buy
58,700
+12,800
+28% +$56.4K ﹤0.01% 8927
2025
Q2 		$157K Sell
45,900
-9,000
-16% -$22.4K ﹤0.01% 8713
2025
Q1 		$122K Buy
54,900
+34,700
+172% +$99.5K ﹤0.01% 8708
2024
Q4 		$59.2K Buy
+20,200
New +$56.3K ﹤0.01% 8925
2024
Q3 		– Sell
-24,700
Closed -$73.1K – 9478
2024
Q2 		$73.1K Sell
24,700
-13,200
-35% -$49.9K ﹤0.01% 8835
2024
Q1 		$172K Sell
37,900
-117,700
-76% -$601K ﹤0.01% 8269
2023
Q4 		$888K Buy
155,600
+22,600
+17% +$105K ﹤0.01% 5762
2023
Q3 		$612K Sell
133,000
-41,800
-24% -$254K ﹤0.01% 5969
2023
Q2 		$1.13M Buy
174,800
+10,800
+7% +$73.7K ﹤0.01% 5021
2023
Q1 		$1.24M Buy
164,000
+33,700
+26% +$306K ﹤0.01% 4621
2022
Q4 		$1.32M Sell
130,300
-99,700
-43% -$1.15M ﹤0.01% 4533
2022
Q3 		$2.27M Buy
230,000
+119,100
+107% +$1.31M ﹤0.01% 3977
2022
Q2 		$1.18M Sell
110,900
-844,500
-88% -$7.15M ﹤0.01% 5176
2022
Q1 		$9.31M Buy
955,400
+221,700
+30% +$2.1M ﹤0.01% 2091
2021
Q4 		$10.5M Sell
733,700
-438,600
-37% -$6.66M ﹤0.01% 1826
2021
Q3 		$23.5M Buy
1,172,300
+715,100
+156% +$12.6M 0.01% 1034
2021
Q2 		$10.1M Buy
457,200
+449,200
+5,615% +$12.4M ﹤0.01% 1698
2021
Q1 		$272K Buy
+8,000
New +$319K ﹤0.01% 7832

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's ABCL Position: Q1 2026 in Review

Jane Street reduced its AbCellera Biologics (ABCL) stake by 39% in Q1 2026, selling an estimated $1.98M and leaving 847,883 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #4372.

Jane Street first reported a position in ABCL in Q4 2020 and has held it in 20 quarters since. The position peaked at $5.49M in Q4 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Jane Street held 847,883 shares of AbCellera Biologics worth $2.96M as of Q1 2026.
  • Jane Street sold 549,205 AbCellera Biologics shares in Q1 2026, an estimated $1.98M.
  • AbCellera Biologics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4372 holding.
  • Jane Street first reported a position in AbCellera Biologics in Q4 2020 and has held it in 20 quarters since.
  • Jane Street's AbCellera Biologics position peaked at $5.49M in Q4 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.